Arcutis Biotherapeutics (ARQT) Insider Trading & Ownership $10.18 +0.09 (+0.89%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage9.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$1.18 M Get ARQT Insider Trade Alerts Want to know when executives and insiders are buying or selling Arcutis Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ARQT Insider Buying and Selling by Quarter Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Arcutis Biotherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/19/2024Masaru MatsudaInsiderSell1,775$9.68$17,182.00 11/15/2024Patrick BurnettInsiderSell100$10.03$1,003.00 11/11/2024Terrie CurranDirectorSell8,687$10.85$94,253.95 11/4/2024Masaru MatsudaInsiderSell5,015$8.68$43,530.20 11/1/2024Howard G WelgusDirectorSell10,000$8.65$86,500.00 10/2/2024Larry Todd EdwardsSVPSell3,725$10.01$37,287.25 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/1/2024Howard G WelgusDirectorSell10,000$9.26$92,600.00 9/24/2024David Joseph TopperCFOSell11,626$9.48$110,214.48 9/3/2024Howard G WelgusDirectorSell10,000$10.77$107,700.00 8/19/2024Patrick BurnettInsiderSell1,728$8.29$14,325.12 8/2/2024Masaru MatsudaInsiderSell5,220$9.02$47,084.40 8/1/2024Howard G WelgusDirectorSell10,000$9.87$98,700.00 7/1/2024Howard G WelgusDirectorSell10,000$9.31$93,100.00 5/30/2024Patrick BurnettInsiderSell23,000$8.75$201,250.00 5/28/2024Masaru MatsudaInsiderSell1,775$9.01$15,992.75 5/17/2024Larry Todd EdwardsSVPSell7,640$8.98$68,607.20 3/4/2024Masaru MatsudaInsiderSell3,760$11.12$41,811.20 1/2/2024Patrick BurnettInsiderSell1,325$3.54$4,690.50 11/21/2023Masaru MatsudaInsiderSell1,850$1.98$3,663.00 (Data available from 1/1/2013 forward) ARQT Insider Trading Activity - Frequently Asked Questions Who is on Arcutis Biotherapeutics's Insider Roster? The list of insiders at Arcutis Biotherapeutics includes David Joseph Topper, David W Osborne, Howard G Welgus, Larry Todd Edwards, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows, Terrie Curran, and Todd Franklin Watanabe. Learn more on insiders at ARQT. What percentage of Arcutis Biotherapeutics stock is owned by insiders? 9.50% of Arcutis Biotherapeutics stock is owned by insiders. Learn more on ARQT's insider holdings. Which Arcutis Biotherapeutics insiders have been buying company stock? The following insider purchased ARQT shares in the last 24 months: Life Sciences Viii L Frazier ($200,000.00). How much insider buying is happening at Arcutis Biotherapeutics? Insiders have purchased a total of 80,000 ARQT shares in the last 24 months for a total of $200,000.00 bought. Which Arcutis Biotherapeutics insiders have been selling company stock? The following insiders have sold ARQT shares in the last 24 months: David Joseph Topper ($110,214.48), Howard G Welgus ($960,380.00), Larry Todd Edwards ($105,894.45), Masaru Matsuda ($214,824.35), Patricia A Turney ($50,484.74), Patrick Burnett ($254,707.57), Scott L Burrows ($33,867.60), Terrie Curran ($94,253.95), and Todd Franklin Watanabe ($186,937.17). How much insider selling is happening at Arcutis Biotherapeutics? Insiders have sold a total of 184,929 Arcutis Biotherapeutics shares in the last 24 months for a total of $2,011,564.31 sold. Arcutis Biotherapeutics Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Compensation: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Compensation: $60.83kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Compensation: $722.94kMr. L. Todd Edwards (Age 60)Senior VP & Chief Commercial Officer Compensation: $755.64k1 recent tradesMr. David J. Topper (Age 66)Senior VP & Chief Financial Officer Mr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Mr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Compensation: $626.22k4 recent tradesMs. Amanda SheldonHead of Corporate Communications More Insider Trading Tools from MarketBeat Related Companies Innoviva Insider Ownership Ocular Therapeutix Insider Ownership Kiniksa Pharmaceuticals Insider Ownership Phathom Pharmaceuticals Insider Ownership ORIC Pharmaceuticals Insider Ownership Supernus Pharmaceuticals Insider Ownership Nkarta Insider Ownership Karyopharm Therapeutics Insider Ownership BioXcel Therapeutics Insider Ownership Biohaven Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:ARQT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
